List view / Grid view
Chemical crosslinking coupled with mass spectrometry (XL-MS) has been used for many years to study protein structure and function. However, recent advances in MS technology, as well as crosslinking reagents and data analysis tools, mean the technique has truly come of age. Here, Albert JR Heck, Alexander Makarov, Henning Urlaub…
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how to maximise the potential of mass spectrometry.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A new discovery could lead to the development of a drug for untreatable strains of TB, which can target uptake of the very amino acid that enables the bacteria to spread within the body.
A new mechanism has been reported for detecting foreign material during early immune responses which may help detect elusive cancers.
A study has used a proteomic method to uncover why some melanoma tumours do not respond to immunotherapy, which could improve treatments.
A recent study has identified the DBC1 gene which leaves cancer cells more exposed to therapies.
Researchers have found an enzyme and its counterpart which inhibit T-cells from attacking tumour cells.
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
In this issue: novel approaches to produce radiolabelled antibodies, the use of CRISPR/Cas9 to accelerate the development of targeted therapies and utilisation of stem cells to study the effects of cannabis on neuronal development.
Researchers succeed in using machine learning to make the mass analysis of proteins faster and almost error-free.
New method for computational mass spectrometry will speed up the discovery of natural products that could be used in medicines...
Over the last five years drug discovery has undergone a rapid evolution from a closed and proprietary endeavour to an open and collaborative process. Large and small pharma now openly collaborate with each other and the wider academic world to leverage their collective depth of knowledge to increase the chances…
